Stockscreener 앱 받기
3.87
8.73%
-0.37
시간 외 거래:
3.88
0.010
+0.26%
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech raises $152 million via two issues - Biostock
Alvotech prices $152M share offering and private placement to fund biosimilar development - Pluang
Alvotech Prices Public Offering of 22.7 Million Ordinary Shares at $3.75 per Share - Quiver Quantitative
Alvotech Prices Offering Of 22.67 Million Ordinary Shares At $3.75 Per Share - TradingView
Alvotech's $125M Gamble: Fueling a Biosimilar Pipeline Amidst Headwinds - BriefGlance
Jefferies (JEF) Involved in Alvotech's Share Issuance Suspension - GuruFocus
ALVO SEC FilingsAlvotech 10-K, 10-Q, 8-K Forms - Stock Titan
Alvotech (ALVO) launches shelf offering; concurrent EEA private placement indicated - Stock Titan
Alvotech initiates $125M fundraising via public and private offering for biosimilar growth - MSN
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares - The Manila Times
Alvotech (ALVO) terminates Jefferies ATM share prospectus - Stock Titan
Alvotech seeks $125M to fund biosimilar medicines via share sale - Stock Titan
Alvotech Stock (LU2557688560): Nordic-listed biosimilar player draws focus after latest trading move - AD HOC NEWS
Alvotech seeks FDA nod for Simponi, Eylea biosimilars again - Drug Store News
Alvotech announced that it expects to receive $66.849998 million in funding - marketscreener.com
Why Alvotech (ALVO) Is Up 17.8% After FDA Advances Its Entyvio Biosimilar AVT16 Application - simplywall.st
Alvotech hits critical inflection as biosimilar pipeline nears FDA decisions - MSN
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? - The Motley Fool
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) - MSN
Alvotech gains on FDA acceptance of Entyvio biosimilar BLA - MSN
Alvotech allocates shares to a board director as part of his pay package, filed with Luxembourg regulator. - Pluang
Transactions of Managers and Closely Associated Persons - Stock Titan
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions - MarketBeat
Transcript : Alvotech Presents at UBS Virtual Generics and Biosimilars Day, Jun-10-2026 10 - marketscreener.com
Alvotech seeks US nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again - MSN
ALVO: Poised for rapid biosimilar expansion, targeting key launches and market leadership by 2027 - TradingView
Alvotech (ALVO) Returns To Quarterly Profitability Challenging Concern Over Persistent Losses - simplywall.st
Alvotech resubmits BLA for proposed Eylea biosimilar - Eyes On Eyecare
Alvotech Takes The Lead On Vedolizumab - Citeline News & Insights
Assessing Alvotech (ALVO) Valuation After FDA Acceptance Of AVT16 Biosimilar Application - simplywall.st
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads - RTTNews
Alvotech (ALVO) Secures FDA Review for New Biosimilar AVT16 - GuruFocus
Alvotech (NASDAQ: ALVO) Q1 2026 results and FDA review of key biosimilars - Stock Titan
FDA to review biosimilar of Entyvio - Managed Healthcare Executive
Alvotech (ALVO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Biggest stock movers Monday: NRIX, INTC, and more (NASDAQ:NRIX) - Seeking Alpha
ALVO: Accelerated U.S. biosimilar launches and global expansion drive strong growth outlook - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Alvotech announces FDA acceptance of BLA for AVT16 biosimilar - grafa.com
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements (NASDAQ:ALVO) - Seeking Alpha
US FDA Accepts Alvotech's Biologics License Application for Entyvio Biosimilar - Moomoo
Alvotech stock surges on FDA review of Entyvio biosimilar By Investing.com - Investing.com Canada
Why is Alvotech stock rallying today? - Investing.com UK
FDA accepts Alvotech's application for AVT16, a... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Alvotech stock surges on FDA review of Entyvio biosimilar - Investing.com
2.11%
자본화:
|
볼륨(24시간):